Hebei Mojin Biotechnology Co.,Ltd
Diamond Supplier Enterprise Certification
- Diamond
Supplier - 6th
years
Diamond Supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: 13231137666
Tel: 15028179902
Tel: 13383610321
Tel: +86 13288715578
Tel: 13288715308
Tel: +86 15028179772
Tel: +86 13315458396
Tel: 15103291926
Tel: 13315457394
Mobile: 13231137666
Tel: 13231137666
Fax:
Province/state: Hebei
City: shijiazhuang
Street: room 1401,A building,Enjoy city,shijiazhuang city,hebei province,China
MaxCard:
Ms.betty Ms.mayCAS NO.910463-68-2
medical (1-25)Metric Tonmedical (25-1000)Metric Tonpharmaceutical(1-25)Metric Ton
Our company have high quality product , and also the product we have good manufacture .
First of all, this product is of fine quality. Every finish should be checked by quality inspection system.And every one should be also tried out for one month.Besides，this type has a good viscosity. the prouct can make Gel hand sanitizer thickener cosmetics industry.
We can ensure the product quality , If the product is not satisfactory, you can return it at any time.
our product have resonable price and good service high quality and inexpensive, you deserve.every webiste we have the sales point, your purchase is convenient.
Any time on line , from 0.00-24:00 . if you have any questions , pls contact with me ,As long as you have the need, we will serve you wholeheartedly
| Product Name: | Semaglutide |
| Synonyms: | Sermaglutide;Semaglutide impurity;Sermaglutide USP/EP/BP;semaglutide;Sermaglutide CAS 910463 68 2;Ozempic, Rybelsus;Ozempic;Semaglutide (H-7894.0001) |
| CAS: | 910463-68-2 |
| MF: | C187H291N45O59 |
| MW: | 4113.57754 |
| EINECS: | 203-405-2 |
| Product Categories: | GLP;PP;APIs;API;910463-68-2 |
| Mol File: | 910463-68-2.mol |
| Description | Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) such that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen, or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient. |
| Uses | Semaglutide injection (Wegovy) is used along with an individualized low-calorie, low-fat diet and exercise program to help with weight loss in overweight adults who may also have high blood pressure, diabetes, or high cholesterol. Semaglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Semaglutide injection also works by slowing the movement of food through the stomach and may decrease appetite and cause weight loss. |
| Definition | ChEBI: Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide. |
| Biological Activity | Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM). |
| Mechanism of action | Semaglutide is a glucagon-like peptide-1 receptor agonist. It increases the production of insulin, a hormone that lowers the blood sugar level. It also appears to enhance growth of β cells in the pancreas, which are the sites of insulin production. It also inhibits glucagon, which is a hormone that increases blood sugar. It additionally reduces food intake by lowering appetite and slows down digestion in the stomach. In this way it reduces body fat. |
| Side effects | Side effects including nausea, vomiting, diarrhea, abdominal pain, and constipation may occur. In people with heart problems, it can cause damage to the back of the eye (retinopathy). Side effects include kidney problems, diabetic retinopathy, allergic reactions, low blood sugar, and pancreatitis. |
| in vitro | Semaglutide is selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) is three-fold decreased compared to liraglutide, whereas the albumin affinity is increased. |
| in vivo | The plasma half-life is 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. |